Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2015

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2015
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	15,657			—			—			—		$	15,657
Product revenues		—		$	7,906			—			—			7,906
Royalty and license fee income		—			423			—			—			423
		15,657			8,329			—			—			23,986
Operating expenses:
Cost of clinical laboratory services		9,724			—			—			—			9,724
Cost of product revenues		—			3,779			—			—			3,779
Research and development		—			704		$	105			—			809
Selling, general and administrative		4,935			3,031			—		$	2,180			10,146
Provision for uncollectible accounts receivable		631			(42	)		—			—			589
Legal fee expense		42			(22	)		—			1,935			1,955
Legal settlement, net		—			(170	)		—			—			(170	)
Total operating expenses		15,332			7,280			105			4,115			26,832

Operating income (loss)		325			1,049			(105	)		(4,115	)		(2,846	)

Other income (expense)
Interest		(23	)		6			—			(41	)		(58	)
Other		11			2			—			13			26
Foreign exchange loss		—			(125	)		—			—			(125	)
Income (loss) before income taxes	$	313		$	932		$	(105	)	$	(4,143	)	$	(3,003	)

Depreciation and amortization included above	$	358		$	543		$	—		$	22		$	923

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	—			—			—			—
Selling, general and administrative		9			6			—		$	95			110
Total	$	12		$	6			—		$	95		$	113

Capital expenditures	$	453		$	58		$	—		$	4		$	515

Three months ended April 30, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,542			—			—			—		$	14,542
Product revenues		—		$	8,707			—			—			8,707
Royalty and license fee income		—			729			—			—			729
		14,542			9,436			—			—			23,978
Operating expenses:
Cost of clinical laboratory services		9,784			—			—			—			9,784
Cost of product revenues		—			3,800			—			—			3,800
Research and development		—			599		$	250			—			849
Selling, general and administrative		5,091			3,278			—		$	2,236			10,605
Provision for uncollectible accounts receivable		684			—			—			—			684
Legal fee expense		282			766			—			836			1,911
Legal settlements, net		2,000			(5,100	)					—			(3,100	)
Total operating expenses		17,841			3,343			250			3,099			24,533

Operating income (loss)		(3,299	)		6,093			(250	)		(3,099	)		(555	)

Other income (expense)
Interest		(10	)		4			—			(41	)		(47	)
Other		7			(2	)		—			5			10
Foreign exchange gain		—			144			—			—			144
Income (loss) before income taxes	$	(3,302	)	$	6,239		$	(250	)	$	(3,135	)	$	(448	)

Depreciation and amortization included above	$	351		$	614		$	—		$	23		$	988

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			1			—			—		$	3
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	(4	)		—		$	275			280
Total	$	11		$	(3	)		—		$	275		$	283

Capital expenditures	$	90		$	36		$	—		$	—		$	126

Nine months ended April 30, 2015
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	46,204			—			—			—		$	46,204
Product revenues		—		$	23,631			—			—			23,631
Royalty and license fee income		—			2,067			—			—			2,067
		46,204			25,698			—			—			71,902
Operating expenses:
Cost of clinical laboratory services		29,100			—			—			—			29,100
Cost of product revenues		—			11,292			—			—			11,292
Research and development		—			1,887		$	547			—			2,434
Selling, general and administrative		15,090			8,886			—		$	6,125			30,101
Provision for uncollectible accounts receivable		1,820			(89	)		—			—			1,731
Legal fee expense		174			(74	)		—			7,125			7,225
Legal settlement, net		—			(170	)								(170	)
Total operating expenses		46,184			21,732			547			13,250			81,713

Operating income (loss)		20			3,966			(547	)		(13,250	)		(9,811	)

Other income (expense)
Interest		(63	)		13			—			(126	)		(176	)
Other		18			(34	)		—			44			28
Foreign exchange gain		—			(856	)		—			—			(856	)
Income (loss) before income taxes	$	(25	)	$	3,089		$	(547	)	$	(13,332	)	$	(10,815	)

Depreciation and amortization included above	$	1,072		$	1,656		$	2		$	67		$	2,797

Share-based compensation included in above:
Cost of clinical laboratory services	$	9			—			—			—		$	9
Research and development		—		$	2			—			—			2
Selling, general and administrative		30			9			—		$	269			308
Total	$	39		$	11			—		$	269		$	319

Capital expenditures	$	1,042		$	122		$	—		$	4		$	1,168

Nine months ended April 30, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	43,250			—			—			—		$	43,250
Product revenues		—		$	24,424			—			—			24,424
Royalty and license fee income		—			3,366			—			—			3,366
		43,250			27,790			—			—			71,040
Operating expenses:
Cost of clinical laboratory services		28,785			—			—			—			28,785
Cost of product revenues		—			11,511			—			—			11,511
Research and development		14			1,668		$	816			—			2,498
Selling, general and administrative		15,122			10,098			—		$	5,997			31,217
Provision for uncollectible accounts receivable		2,448			20			—			—			2,468
Legal fee expense		572			803			—			3,413			4,788
Legal settlements, net		2,000			(5,100	)								(3,100	)
Total operating expenses		48,941			19,000			816			9,410			78,167

Operating income (loss)		(5,691	)		8,790			(816	)		(9,410	)		(7,127	)

Other income (expense)
Interest		(32	)		13			—			(142	)		(161	)
Other		34			18			—			33			85
Foreign exchange gain		—			460			—			—			460
Income (loss) before income taxes	$	(5,689	)	$	9,281		$	(816	)	$	(9,519	)	$	(6,743	)

Depreciation and amortization included above	$	1,061		$	1,876		$	6		$	72		$	3,015

Share-based compensation included in above:
Cost of clinical laboratory services	$	6			1			—			—		$	7
Research and development		—		$	1			—			—			1
Selling, general and administrative		28			5			—		$	456			489
Total	$	34		$	7			—		$	456		$	497

Capital expenditures	$	453		$	117		$	—		$	—		$	570

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details